Biological and genetic properties of SA14-14-2, a live-attenuated Japanese encephalitis vaccine that is currently available for humans

Journal of Microbiology

Volumn 50, Issue 4, 2012, Pages 698-706

  Song, Byung Hak ^a   Yun, Gil Nam ^a   Kim, Jin Kyoung ^a   Yun, Sang Im ^a,b   Lee, Young Min ^a,b  

^a Chungbuk National University College of Medicine   (South Korea)

^b UTAH STATE UNIVERSITY   (United States)

Author keywords

complete genome; Japanese encephalitis virus; pathogenesis; SA14 14 2; virulence

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; VIRUS PROTEIN; VIRUS RNA;

3' UNTRANSLATED REGION; ANIMAL; ARTICLE; CELL LINE; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MISSENSE MUTATION; MOSQUITO; MOUSE; PATHOGENICITY; PATHOLOGY; SYRIAN HAMSTER; TIME; VIROLOGY; VIRULENCE; VIRUS CULTURE; VIRUS GENOME;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE; CRICETINAE; CULICIDAE; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; GENOME, VIRAL; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MESOCRICETUS; MICE; MICE, INBRED ICR; MUTAGENESIS, INSERTIONAL; MUTATION, MISSENSE; RNA, VIRAL; TIME FACTORS; VACCINES, ATTENUATED; VIRAL PLAQUE ASSAY; VIRAL PROTEINS; VIRULENCE;

CRICETINAE; FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; MUS;

EID: 84865789169     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-012-2336-6     Document Type: Article

References (103)

1. Ackermann, M. and Padmanabhan, R. 2001. De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. J. Biol. Chem. 276, 39926-39937.
2. Aihara, S., Rao, C. M., Yu, Y. X., Lee, T., Watanabe, K., Komiya, T., Sumiyoshi, H., Hashimoto, H., and Nomoto, A. 1991. Identification of mutations that occurred on the genome of Japanese encephalitis virus during the attenuation process. Virus Genes5, 95-109.
3. Arroyo, J., Guirakhoo, F., Fenner, S., Zhang, Z. X., Monath, T. P., and Chambers, T. J. 2001. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J. Virol. 75, 934-942.
4. Beasley, D. W., Lewthwaite, P., and Solomon, T. 2008. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther. 8, 95-106.
5. Bista, M. B., Banerjee, M. K., Shin, S. H., Tandan, J. B., Kim, M. H., Sohn, Y. M., Ohrr, H. C., Tang, J. L., and Halstead, S. B. 2001. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet358, 791-795.
6. Brinton, M. A. 2002. The molecular biology of West Nile Virus: a new invader of the western hemisphere. Annu. Rev. Microbiol. 56, 371-402.
7. Burke, D. S. and Leake, C. J. 1988. Japanese encephalitis, pp. 63-92. In Monath, T. P. (ed.), The Arboviruses: Epidemiology and Ecology, Vol. 3. CRC, Boca Raton, Florida, USA.
8. Calisher, C. H. and Gould, E. A. 2003. Taxonomy of the virus family Flaviviridae. Adv. Virus Res. 59, 1-19.
9. Campbell, G. L., Hills, S. L., Fischer, M., Jacobson, J. A., Hoke, C. H., Hombach, J. M., Marfin, A. A., Solomon, T., Tsai, T. F., Tsu, V. D., and Ginsburg, A. S. 2011. Estimated global incidence of Japanese encephalitis: a systematic review. Bull. World Health Organ. 89, 766-774, 774A-774E.
10. Centers for Disease Control and Prevention (CDC). 2011. Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb. Mortal. Wkly. Rep. 60, 661-663.
11. Chambers, T. J., Grakoui, A., and Rice, C. M. 1991. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol. 65, 6042-6050.
12. Chambers, T. J., Hahn, C. S., Galler, R., and Rice, C. M. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44, 649-688.
13. Chambers, T. J., Nestorowicz, A., Mason, P. W., and Rice, C. M. 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73, 3095-3101.
14. Diamond, M. S. 2009. Mechanisms of evasion of the type I interferon antiviral response by flaviviruses. J. Interferon Cytokine Res. 29, 521-530.
15. Eckels, K. H., Yu, Y. X., Dubois, D. R., Marchette, N. J., Trent, D. W., and Johnson, A. J. 1988. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine6, 513-518.
16. Egloff, M. P., Benarroch, D., Selisko, B., Romette, J. L., and Canard, B. 2002. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21, 2757-2768.
17. Endy, T. P. and Nisalak, A. 2002. Japanese encephalitis virus: ecology and epidemiology. Curr. Top. Microbiol. Immunol. 267, 11-48.
18. Erlanger, T. E., Weiss, S., Keiser, J., Utzinger, J., and Wiedenmayer, K. 2009. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis. 15, 1-7.
19. Falgout, B., Miller, R. H., and Lai, C. J. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67, 2034-2042.
20. Fischer, M., Lindsey, N., Staples, J. E., and Hills, S. 2010. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59, 1-27.
21. Gubler, D. J., Kuno, G., and Markoff, L. 2007. Flaviviruses, pp. 1153-1252. In Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., and Straus, S. E. (eds.), Fields virology, 5th ed. Lippincott Williams & Wilkins Publishers, Philadelphia, Pennsylvania, USA.
22. Guirakhoo, F., Zhang, Z. X., Chambers, T. J., Delagrave, S., Arroyo, J., Barrett, A. D., and Monath, T. P. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology257, 363-372.
23. Guo, J. T., Hayashi, J., and Seeger, C. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79, 1343-1350.
24. Halstead, S. B. and Jacobsen, J. 2008. Japanese encephalitis vaccines, pp. 311-352. In Plotkin, S. A., Orenstein, W. A., and Offit, P. A. (eds.), Vaccines, 5th ed. Saunders Elsevier, Maryland Heights, Missouri, USA.
25. Halstead, S. B. and Thomas, S. J. 2010. Japanese encephalitis: new options for active immunization. Clin. Infect. Dis. 50, 1155-1164.
26. Halstead, S. B. and Thomas, S. J. 2011. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines10, 355-364.
27. Hanna, J. N., Ritchie, S. A., Phillips, D. A., Lee, J. M., Hills, S. L., van den Hurk, A. F., Pyke, A. T., Johansen, C. A., and Mackenzie, J. S. 1999. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170, 533-536.
28. Hanna, J. N., Ritchie, S. A., Phillips, D. A., Shield, J., Bailey, M. C., Mackenzie, J. S., Poidinger, M., McCall, B. J., and Mills, P. J. 1996. An outbreak of Japanese encephalitis in the Torres Strait, Australia, 1995. Med. J. Aust. 165, 256-260.
29. Harrison, S. C. 2008. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690-698.
30. Hase, T., Dubois, D. R., Summers, P. L., Downs, M. B., and Ussery, M. A. 1993. Comparison of replication rates and pathogenicities between the SA14 parent and SA14-14-2 vaccine strains of Japanese encephalitis virus in mouse brain neurons. Arch. Virol. 130, 131-143.
31. Hennessy, S., Liu, Z., Tsai, T. F., Strom, B. L., Wan, C. M., Liu, H. L., Wu, T. X., Yu, H. J., Liu, Q. M., Karabatsos, N., andet al. 1996. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet347, 1583-1586.
32. Igarashi, A., Tanaka, M., Morita, K., Takasu, T., Ahmed, A., Ahmed, A., Akram D. S., and Waqar, M. A. 1994. Detection of west Nile and Japanese encephalitis viral genome sequences in cerebrospinal fluid from acute encephalitis cases in Karachi, Pakistan. Microbiol. Immunol. 38, 827-830.
33. Issur, M., Geiss, B. J., Bougie, I., Picard-Jean, F., Despins, S., Mayette, J., Hobdey, S. E., and Bisaillon, M. 2009. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA15, 2340-2350.
34. Jelinek, T. 2008. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines7, 689-693.
35. Jelinek, T. 2009. Ixiaro: a new vaccine against Japanese encephalitis. Expert Rev. Vaccines8, 1501-1511.
36. Kang, S. Y., Yun, S. I., Lim, Y. H., and Lee, Y. M. 2004. Expression of the structural proteins of Japanese encephalitis virus. J. Bacteriol. Virol. 34, 75-81.
37. Kim, J. M., Yun, S. I., Song, B. H., Hahn, Y. S., Lee, C. H., Oh, H. W., and Lee, Y. M. 2008. A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis, virus particle release, and pathogenicity in mice. J. Virol. 82, 7846-7862.
38. Kollaritsch, H., Paulke-Korinek, M., and Dubischar-Kastner, K. 2009. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9, 921-931.
39. Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E., Jones, C. T., Mukhopadhyay, S., Chipman, P. R., Strauss, E. G., andet al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell108, 717-725.
40. Kümmerer, B. M. and Rice, C. M. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76, 4773-4784.
41. Lai, C. J. and Monath, T. P. 2003. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv. Virus Res. 61, 469-509.
42. Leung, J. Y., Pijlman, G. P., Kondratieva, N., Hyde, J., Mackenzie, J. M., and Khromykh, A. A. 2008. Role of nonstructural protein NS2A in flavivirus assembly. J. Virol. 82, 4731-4741.
43. Li, H., Clum, S., You, S., Ebner, K. E., and Padmanabhan, R. 1999. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J. Virol. 73, 3108-3116.
44. Lindenbach, B. D. and Rice, C. M. 2003. Molecular biology of flaviviruses. Adv. Virus Res. 59, 23-61.
45. Lindenbach, B. D., Thiel, H. J., and Rice, C. M. 2007. Flaviviridae: the viruses and their replication, pp. 1101-1152. In Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., and Straus, S. E. (eds.), Fields virology, 5th ed. Lippincott Williams & Wilkins Publishers, Philadelphia, Pennsylvania, USA.
46. Liu, W. J., Chen, H. B., and Khromykh, A. A. 2003. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77, 7804-7813.
47. Liu, Z. L., Hennessy, S., Strom, B. L., Tsai, T. F., Wan, C. M., Tang, S. C., Xiang, C. F., Bilker, W. B., Pan, X. P., Yao, Y. J., andet al. 1997. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26, 239 subjects. J. Infect. Dis. 176, 1366-1369.
48. Liu, W. J., Wang, X. J., Mokhonov, V. V., Shi, P. Y., Randall, R., and Khromykh, A. A. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79, 1934-7942.
49. Liu, X., Yu, Y., Li, M., Liang, G., Wang, H., Jia, L., and Dong, G. 2011. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China. Vaccine29, 2127-2130.
50. Mackenzie, J. S., Barrett, A. D., and Deubel, V. 2002a. The Japanese encephalitis serological group of flaviviruses: a brief introduction to the group. Curr. Top. Microbiol. Immunol. 267, 1-10.
51. Mackenzie, J. S., Gubler, D. J., and Petersen, L. R. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10, S98-109.
52. Mackenzie, J. S., Johansen, C. A., Ritchie, S. A., van den Hurk, A. F., and Hall, R. A. 2002b. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr. Top. Microbiol. Immunol. 267, 49-73.
53. Mackenzie, J. S., Williams, D. T., and Smith, D. W. 2007. Japanese encephalitis virus: the geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas, pp. 201-268. In Tabor, E. (ed.), Emerging viruses in human populations, Elsevier, Amsterdam, Netherlands.
54. Markoff, L. 2003. 5′- and 3′-noncoding regions in flavivirus RNA. Adv. Virus Res. 59, 177-228.
55. Monath, T. P. 2002. Japanese encephalitis vaccines: current vaccines and future prospects. Curr. Top. Microbiol. Immunol. 267, 105-138.
56. Monath, T. P., Levenbook, I., Soike, K., Zhang, Z. X., Ratterree, M., Draper, K., Barrett, A. D., Nichols, R., Weltzin, R., Arroyo, J., andet al. 2000. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol. 74, 1742-1751.
57. Monath, T. P., Soike, K., Levenbook, I., Zhang, Z. X., Arroyo, J., Delagrave, S., Myers, G., Barrett, A. D., Shope, R. E., Ratterree, M., andet al. 1999. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine17, 1869-1882.
58. Mukhopadhyay, S., Kim, B. S., Chipman, P. R., Rossmann, M. G., and Kuhn, R. J. 2003. Structure of West Nile virus. Science302, 248.
59. Mukhopadhyay, S., Kuhn, R. J., and Rossmann, M. G. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3, 13-22.
60. Muñoz-Jordán, J. L., Laurent-Rolle, M., Ashour, J., Martínez-Sobrido, L., Ashok, M., Lipkin, W. I., and García-Sastre, A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79, 8004-8013.
61. Muñoz-Jordán, J. L., Sánchez-Burgos, G. G., Laurent-Rolle, M., and García-Sastre, A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA100, 14333-14338.
62. Ni, H., Burns, N. J., Chang, G. J., Zhang, M. J., Wills, M. R., Trent, D. W., Sanders, P. G., and Barrett, A. D. 1994. Comparison of nucleotide and deduced amino acid sequence of the 5 non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75, 1505-1510.
63. Ni, H., Chang, G. J., Xie, H., Trent, D. W., and Barrett, A. D. 1995. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J. Gen. Virol. 76, 409-413.
64. Nitayaphan, S., Grant, J. A., Chang, G. J., and Trent, D. W. 1990. Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14- 14-2. Virology177, 541-552.
65. Ohrr, H., Tandan, J. B., Sohn, Y. M., Shin, S. H., Pradhan, D. P., and Halstead, S. B. 2005. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet366, 1375-1378.
66. Paranjape, S. M. and Harris, E. 2010. Control of dengue virus translation and replication. Curr. Top. Microbiol. Immunol. 338, 15-34.
67. Patkar, C. G. and Kuhn, R. J. 2008. Yellow Fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. J. Virol. 82, 3342-3352.
68. Paul, W. S., Moore, P. S., Karabatsos, N., Flood, S. P., Yamada, S., Jackson, T., and Tsai, T. F. 1993. Outbreak of Japanese encephalitis on the island of Saipan, 1990. J. Infect. Dis. 167, 1053-1058.
69. Pijlman, G. P., Kondratieva, N., and Khromykh, A. A. 2006. Translation of the flavivirus kunjin NS3 gene in cis but not its RNA sequence or secondary structure is essential for efficient RNA packaging. J. Virol. 80, 11255-11264.
70. Plesner, A. M. 2003. Allergic reactions to Japanese encephalitis vaccine. Immunol. Allergy Clin. North Am. 23, 665-697.
71. Ray, D., Shah, A., Tilgner, M., Guo, Y., Zhao, Y., Dong, H., Deas, T. S., Zhou, Y., Li, H., and Shi, P. Y. 2006. West Nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J. Virol. 80, 8362-8370.
72. Rice, C. M., Lenches, E. M., Eddy, S. R., Shin, S. J., Sheets, R. L., and Strauss, J. H. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science229, 726-733.
73. Robertson, S. J., Mitzel, D. N., Taylor, R. T., Best, S. M., and Bloom, M. E. 2009. Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures. Immunol. Res. 43, 172-186.
74. Rosen, L. 1986. The natural history of Japanese encephalitis virus. Annu. Rev. Microbiol. 40, 395-414.
75. Sakaguchi, M., Miyazawa, H., and Inouye, S. 2001. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy56, 536-539.
76. Sohn, Y. M., Park, M. S., Rho, H. O., Chandler, L. J., Shope, R. E., and Tsai, T. F. 1999. Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants. Vaccine17, 2259-2264.
77. Sohn, Y. M., Tandan, J. B., Yoksan, S., Ji, M., and Ohrr, H. 2008. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine26, 1638-1643.
78. Solomon, T. 2006. Control of Japanese encephalitis-within our grasp? N. Engl. J. Med. 355, 869-871.
79. Solomon, T. and Vaughn, D. W. 2002. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol. 267, 171-194.
80. Solomon, T. and Winter, P. M. 2004. Neurovirulence and host factors in flavivirus encephalitis-evidence from clinical epidemiology. Arch. Virol. Suppl. S18, 161-170.
81. Sumiyoshi, H., Mori, C., Fuke, I., Morita, K., Kuhara, S., Kondou, J., Kikuchi, Y., Nagamatu, H., and Igarashi, A. 1987. Complete nucleotide sequence of the Japanese encephalitis virus genome RNA. Virology161, 497-510.
82. Tan, B. H., Fu, J., Sugrue, R. J., Yap, E. H., Chan, Y. C., and Tan, Y. H. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology216, 317-325.
83. Tandan, J. B., Ohrr, H., Sohn, Y. M., Yoksan, S., Ji, M., Nam, C. M., and Halstead, S. B. 2007. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine25, 5041-5045.
84. Thiel, H. J., Collett, M. S., Gould, E. A., Heinz, F. X., Houghton, M., Meyers, G., Purcell, R. H., and Rice, C. M. 2005. Family Flaviviridae, pp. 981-998. In Fauquet, C. M., Mayo, M. A., Maniloff, J., Desselberger, U., and Ball, L. A. (eds.), Virus taxonomy: eighth report of the international committee on taxonomy of viruses. Elsevier Academic Press, San Diego, California, USA.
85. Tsai, T. F. 2000. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine18, 1-25.
86. Tsai, T. F., Yu, Y. X., Jia, L. L., Putvatana, R., Zhang, R., Wang, S., and Halstead, S. B. 1998. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine-a comparison of 1- and 3-month immunization schedules. J. Infect. Dis. 177, 221-223.
87. van den Hurk, A. F., Ritchie, S. A., and Mackenzie, J. S. 2009. Ecology and geographical expansion of Japanese encephalitis virus. Annu. Rev. Entomol. 54, 17-35.
88. Villordo, S. M. and Gamarnik, A. V. 2009. Genome cyclization as strategy for flavivirus RNA replication. Virus Res. 139, 230-239.
89. Weaver, S. C. and Barrett, A. D. 2004. Transmission cycles, host range, evolution and emergence of arboviral disease. Nat. Rev. Microbiol. 2, 789-801.
90. Weaver, S. C. and Reisen, W. K. 2010. Present and future arboviral threats. Antiviral Res. 85, 328-345.
91. Wengler, G. and Wengler, G. 1991. The carboxy-terminal part of the NS3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology184, 707-715.
92. Wengler, G. and Wengler, G. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology197, 265-273.
93. Westaway, E. G., Mackenzie, J. M., and Khromykh, A. A. 2002. Replication and gene function in Kunjin virus. Curr. Top. Microbiol. Immunol. 267, 323-351.
94. Wilder-Smith, A. and Halstead, S. B. 2010. Japanese encephalitis: update on vaccines and vaccine recommendations. Curr. Opin. Infect. Dis. 23, 426-431.
95. World Health Organization (WHO). 2005. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly. Epidemiol. Rec. 80, 242-243.
96. World Health Organization (WHO). 2006. Japanese encephalitis vaccines: WHO position paper. Wkly. Epidemiol. Rec. 81, 331-340.
97. World Health Organization (WHO). 2008. Global advisory committee on vaccine safety, 12-13 December 2007. Wkly. Epidemiol. Rec. 83, 37-44.
98. Xin, Y. Y., Ming, Z. G., Peng, G. Y., Jian, A., and Min, L. H. 1988. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am. J. Trop. Med. Hyg. 39, 214-217.
99. Yu, Y. 2010. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine28, 3635-3641.
100. Yun, S. I., Kim, S. Y., Choi, W. Y., Nam, J. H., Ju, Y. R., Park, K. Y., Cho, H. W., and Lee, Y. M. 2003a. Molecular characterization of the full-length genome of the Japanese encephalitis viral strain K87P39. Virus Res. 96, 129-140.
101. Yun, S. I., Kim, S. Y., Rice, C. M., and Lee, Y. M. 2003b. Development and application of a reverse genetics system for Japanese encephalitis virus. J. Virol. 77, 6450-6465.
102. Yun, S. I. and Lee, Y. M. 2006. Japanese encephalitis virus: molecular biology and vaccine development, pp. 225-271. In Kalitzky, M., and Borowski, P. (eds.), Molecular biology of the flavivirus. Horizon Scientific Press, Norwich, UK.
103. Zhang, W., Chipman, P. R., Corver, J., Johnson, P. R., Zhang, Y., Mukhopadhyay, S., Baker, T. S., Strauss, J. H., Rossmann, M. G., and Kuhn, R. J. 2003. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10, 907-912.